Literature DB >> 8972919

Cannabis: pharmacology and toxicology in animals and humans.

I B Adams1, B R Martin.   

Abstract

Cannabis is one of the most widely used drugs throughout the world. The psychoactive constituent of cannabis, delta 9-tetrahydrocannabinol (delta 9-THC), produces a myriad of pharmacological effects in animals and humans. For many decades, the mechanism of action of cannabinoids, compounds which are structurally similar to delta 9-THC, was unknown. Tremendous progress has been made recently in characterizing cannabinoid receptors both centrally and peripherally and in studying the role of second messenger systems at the cellular level. Furthermore, an endogenous ligand, anandamide, for the cannabinoid receptor has been identified. Anandamide is a fatty-acid derived compound that possesses pharmacological properties similar to delta 9-THC. The production of complex behavioral events by cannabinoids is probably mediated by specific cannabinoid receptors and interactions with other neurochemical systems. Cannabis also has great therapeutic potential and has been used for centuries for medicinal purposes. However, cannabinoid-derived drugs on the market today lack specificity and produce many unpleasant side effects, thus limiting therapeutic usefulness. The advent of highly potent analogs and a specific antagonist may make possible the development of compounds that lack undesirable side effects. The advancements in the field of cannabinoid pharmacology should facilitate our understanding of the physiological role of endogenous cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972919

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  90 in total

1.  The cannabis policy debate: finding a way forward.

Authors:  W Hall
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

Review 2.  Manipulation of the endocannabinoid system by a general anaesthetic.

Authors:  Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

3.  Severe toxicity following synthetic cannabinoid ingestion.

Authors:  J Lapoint; L P James; C L Moran; L S Nelson; R S Hoffman; J H Moran
Journal:  Clin Toxicol (Phila)       Date:  2011-10       Impact factor: 4.467

4.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 5.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 7.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

10.  The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase.

Authors:  Sachin Patel; Eric R Wohlfeil; David J Rademacher; Erica J Carrier; LaToya J Perry; Abhijit Kundu; J R Falck; Kasem Nithipatikom; William B Campbell; Cecilia J Hillard
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.